Research
Hormonal
Testosterone replacement therapy (TRT) is contraindicated in men with untreated prostate or breast cancer, and is not recommended for improving cognitive function, depressive symptoms, or exercise capacity in hypogonadal men.
Do not take testosterone to fix your memory, mood, or physical frailty. It is not effective for these issues. Also, do not take it if you have untreated prostate or breast cancer.
GoodRefutesHIGH confidence
TRT is contraindicated in men with untreated prostate or breast cancer... We recommend against TRT in frail men to improve exercise capacity/physical function... We recommend against TRT in aging men to improve cognitive function... We recommend against TRT for the sole treatment to improve depressive symptoms in hypogonadal men
Why this rating
Strong recommendations (GRADE 1) based on lack of efficacy evidence.
Source
European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males
Giovanni Corona et al. · Andrology · 2020
DOI 10.1111/andr.12770
clinical_guidelineCited 398×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Testosterone replacement therapy (TRT) reliably improves global sexual function (libido, erectile function, sexual satisfaction) in men with functional hypogonadism in the short term.Good
- Lifestyle changes, specifically weight reduction and physical exercise, are the first-line approach for overweight and obese men with functional hypogonadism because weight loss can increase testosterone concentrations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →